LSTA

Lisata Therapeutics, Inc. (LSTA) Management Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Execution

Management is not demonstrating operating leverage, with TTM operating margin at -164.27% and EBITDA margin at -160.07%.

Revenue efficiency remains extremely poor, with asset turnover at 0.01 and working capital turnover at 0.01.

Cash generation is negative, with TTM free cash flow per share at -1.35 and operating cash flow per share at -1.35.

Capital Allocation

The balance sheet is currently debt-light, with debt-to-assets and debt-to-equity both at 0.0.

However, the company is not creating value from capital, with ROIC at -1.99% and ROE at -1.14%.

Liquidity is adequate in the near term, with a current ratio of 3.69 and cash ratio of 3.50.

Incentives & Governance

No recent news or disclosures indicate a change in management incentives or governance quality.

The operating profile suggests management is still under pressure to improve profitability and cash discipline.

There is no evidence this month of a governance catalyst or accountability improvement.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →